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Mammalian target of rapamycin (mTOR) is a serine-
threonine kinase member of the cellular phosphatidyl-
inositol 3-kinase (PI3K) pathway, which is involved in
multiple functions such as transcriptional and translational
control. Activation of mTOR as a consequence of nutrients
and growth factors results in the phosphorylation and
activation of the 40S ribosomal protein S6 kinase
(p70S6K) and the eukaryotic initiation factor 4E-binding
protein-1 (4EBP1; Fig. 1). These proteins play a key role in
ribosomal biogenesis and cap-dependent translation,
which result in increased translation of mRNAs that are
important to the control and progression of the cell cycle.
mTOR is a downstream mediator in the PI3K/Akt signaling
pathway and plays a critical role in cell survival.
It has been shown that Akt regulates mTOR through the
tuberous sclerosis (TSC) complex [1]. Under non-
stimulated conditions, the TSC complex acts as a negative
regulator of mTOR. Phosphorylation of TSC2 (tuberin) by
Akt inactivates the complex, releasing its inhibitory effects
on mTOR and resulting in mTOR activation. In addition,
TSC regulation of mTOR is mediated by the small G
protein Rheb. When in its GTP state, Rheb is a potent
activator of mTOR. Phosphorylated TSC shifts Rheb to
the inactive GDP state [2].
In breast cancer the PI3K/Akt pathway can be activated
by membrane receptors, including the HER (or ErbB)
family of growth factor receptors, the insulin-like growth
factor (IGF) receptor, and the estrogen receptor (ER) [3].
Stimulation of the PI3K/Akt pathway can also occur
through oncogenic Ras. There is evidence suggesting that
Akt promotes breast cancer cell survival and resistance to
chemotherapy, trastuzumab, and tamoxifen [4–7]. This
suggests that targeting the Akt/PI3K pathway with mTOR
antagonists may increase the therapeutic efficacy of
breast cancer therapy. Rapamycin and rapamycin analogs
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Abstract
Mammalian target of rapamycin (mTOR) is a serine-threonine kinase member of the cellular
phosphatidylinositol 3-kinase (PI3K) pathway, which is involved in multiple biologic functions such as
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a specific mTOR antagonist that targets this pathway and blocks the downstream signaling elements,
resulting in cell cycle arrest in the G1 phase. Targeting the Akt/PI3K pathway with mTOR antagonists
may increase the therapeutic efficacy of breast cancer therapy.
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(CCI-779, RAD001, AP23573) are specific mTOR
antagonists that are used to target this pathway and block
the downstream signaling elements and result in cell cycle
arrest in the G1 phase. These agents have exhibited
impressive growth inhibitory effects against a broad range
of human cancers, including breast cancer, in preclinical
and early clinical evaluations [8,9].
Rapamycin is a macrolytic lactone produced by
Streptomyces  hygroscopicus, which has immuno-
suppressive, antimicrobial, and antitumor properties.
Rapamycin binds intracellularly to FK506 binding protein-
12 (tacrolimus-binding protein) and targets a principal
protein kinase that was named mTOR. Other names
include FKBP-rapamycin associated protein (FRAP),
rapamycin FKBP12 target (RAFT1), and rapamycin target
(RAPT1). Inhibition of the phosphorylation of mTOR by
rapamycin specifically blocks the activation of the 40S
ribosomal protein S6 kinase and 4E-binding protein-1, and
directly reduces the translation of mRNAs that encode
essential components of the protein synthesis machinery,
including growth factors, oncoproteins, and cell cycle
regulators. Rapamycin treatment also results in prevention
of cyclin-dependent kinase activation, inhibition of
phosphorylation of the retinoblastoma protein, and
acceleration of the turnover of cyclin D1 mRNA and
protein, leading to a deficiency of active cyclin-dependent
kinase 4/cyclin D1 complexes. The combination of these
events likely contributes to the prominent inhibitory effects
of rapamycin at the G1/S boundary of the cell cycle,
induction of apoptosis, and inhibition of angiogenesis in
several preclinical cancer models [10].
Rapamycin was found to be a potent fungicide,
particularly against Candida albicans and other
filamentous fungi. Later, another related derivative was
identified and found to be a potent immunosuppressant
(tacrolimus). In bone marrow transplant research, further
evaluation of the immunosuppressive qualities of
rapamycin revealed successful activity in reversing acute
allograft rejection and enhancing long-term donor-specific
allograft tolerance. Because this drug is a potent immuno-
suppressant with negligible toxicity, it has regulatory
approval for use in the prevention of allograft rejection
after organ transplantation.
Rapamycin was found to have antiproliferative actions in a
diverse range of experimental tumors, including lymphoma,
small cell lung cancer, and rhabdomyosarcoma [11–13].
Antitumor actions of rapamycin have been principally
attributed to its ability to modulate the synthesis of critical
proteins that are required for ribosome biosynthesis,
protein translation, and G1 to S cell cycle phase progres-
sion. Rapamycin’s poor aqueous solubility and chemical
stability limited its development as an anticancer agent,
and consequently rapamycin analogs with more favorable
pharmaceutical characteristics were developed, including
CCI-779, RAD 001, and AP23573.
Although not all of the relevant elements of rapamycin-
sensitive signal transduction pathways have been
elucidated, PI3K/Akt appears to be the key modulating
element in the upstream pathway by which interactions
between growth factors and growth factor receptors affect
the phosphorylation state of mTOR. The enzyme PI3K,
which plays a central role in cellular proliferation, motility,
neovascularization, viability and senescence, is upregulated
in many types of malignant cells. The best characterized
effector of PI3K is the serine/threonine kinase Akt. Both
PI3K and Akt are proto-oncogenes, because they have
been demonstrated to possess cell-transforming
properties. PI3K has other downstream effectors, but the
Akt pathway is of particular interest because of its role in
inhibiting apoptosis and promoting cell proliferation.
With regard to breast cancer pathogenesis, elements of
the PI3K/Akt pathway have been demonstrated to be
activated by the ErbB family, IGF receptor, and oncogenic
Ras [14–17]. Over-expression of IGF-I receptor and IGF-I
Figure 1
Rapamycin-sensitive signal transduction pathways. Both rapamycin
and rapamycin analogs bind to the immunophilin FK506 binding
protein-12 (FKBP-12). The rapamycin-FKBP12 complex binds to
mammalian target of rapamycin (mTOR), inhibiting its kinase activity,
which in turn inhibits the phosphorylation and activation of the
downstream translational regulators 4EBP1/PHAS-1 and p70S6K.
These downstream effects decrease the translational processing of
mRNA for specific proteins that are essential for G1 to S phase
transition. 4E-BP1, 4E binding protein-1; GF, growth factor; GPB,
growth factor receptor bound; MAP, mitogen activated protein kinase;
PI3K, phosphatidylinositol 3-kinase; PHAS, phosphorylated heat and
acid stable protein; pRb, retinoblastoma protein; PTEN, phosphatase
and tensin homologue deleted from chromosome 10; RAP, rapamycin;
SOS, son-of-sevenless; TSC, tuberous sclerosis complex.221
commonly occurs in breast cancers, and circulating IGF-I
has been related to the risk for developing breast cancer
[18–21]. Furthermore, elements of the IGF signaling
pathway are found to be highly expressed in primary
breast tumors, and overexpression of IGF pathway
elements has been associated with poor prognosis [22].
Upon ligand binding, IGF-I receptor activates insulin
receptor substrates that activate elements that are
involved in signaling through the PI3K/Akt pathway. Breast
tumors can possess genetic alterations in the PI3K/Akt
pathway and often exhibit high levels of constitutive Akt
activity. Recently, a high frequency of mutations of the
PIK3CA gene was reported in 32% of colon cancers and
almost 10% of breast cancers [23]. This may be a useful
tool to identify which patients may respond to rapamycin-
directed therapy.
ER activation can directly drive the PI3K/Akt pathway [24].
Cross-talk between ErB1 and ER has been shown to
activate the PI3K/Akt pathway, which has been associated
with estrogen-independent transcriptional activity and anti-
estrogen resistance [2–5]. In support of this hypothesis,
breast cancer cell lines with constitutively active Akt can
proliferate in the absence of exogenous estrogen and are
resistant to the growth inhibitory and proapoptotic effects
of tamoxifen in vitro and in vivo [25]. The role played by
the PI3K/Akt pathway in the development of estrogen
resistance is also supported by studies of IGF. For
example, IGF-I has been demonstrated to downregulate
the progesterone receptor via a transcriptional mechanism
that involves the PI3K/Akt pathway and is independent of
the ER. These data may provide an explanation for why
progesterone receptor negative tumors are particularly
insensitive to estrogen deprivation [26].
Additional evidence points to a rationale for targeting the
PI3K/Akt pathway in the treatment of breast cancer. Over-
expression of D-type cyclin has been reported in
approximately 50% of invasive breast cancers and was
found to be associated with tumor progression [27,28].
Upstream regulators of the PI3K/Akt pathway include the
tumor suppressor gene PTEN (phosphatase and tensin
homolog deleted from chromosome 10). PTEN inhibits the
activity of PI3K. Thus, loss of PTEN suppressor gene
function has been associated with Akt activation. A familial
syndrome characterized by germline mutations in PTEN
appear to be responsible for Cowden’s syndrome, which
predisposes to the development of several types of
malignant neoplasms, including breast cancer. Another
familial syndrome is Bannayan–Zonana, which has similar
features. It is important to note that fewer than 5% of
breast tumors harbor a PTEN mutation. However, hemi-
zygous deletions of the PTEN locus and subsequent lack
of PTEN protein occurs in about 30–40% of patients with
sporadic breast cancer. This heterozygosity of the PTEN
locus is associated with an increased activation of Akt
[29–33]. The hyperactivation of PI3K/Akt signaling
elements in PTEN-deficient malignancies suggests that
these cancers are dependent on this pathway for growth
and maintenance. Furthermore, experiments conducted in
PTEN knockout mice indicate that PTEN-deficient
cancers are extraordinarily sensitive to the growth
inhibitory effects of rapamycin and rapamycin analogs
[34]. Interestingly, treatment of doxorubicin-resistant and
PTEN-defective prostate cancer cells with CCI-779 has
been shown to reverse doxorubicin resistance [35].
Transfection of those prostate cancer cells with functional
PTEN produced a similar modulatory effect, suggesting
that doxorubicin resistance in this model is mediated
through the downstream activation of mTOR.
In breast cancer cells, PI3K/Akt and mTOR pathways
appear to be critical for the proliferative responses
mediated by epidermal growth factor receptor, the IGF
receptor and the ER. These findings suggest that it may
be rational to pursue the use of pharmacologic inhibitors
of mTOR in treating patients with breast cancers,
particularly because these malignancies have evidence of
hyperactive PI3K/Akt signaling elements and/or
aberrations in tumor suppressor proteins such as PTEN.
Clinical studies with rapamycin/rapamycin
analogs
The safety and efficacy of rapamycin in the prevention of
organ rejection have been demonstrated in two
randomized, double-blind, multicenter, controlled trials
involving over 1000 adult patients according to the
investigator brochure for CCI-779 formulation. Typical
dosing was 2 mg or 5 mg administered daily. In these and
most other trials, rapamycin has been administered with
cyclosporine and corticosteroids, and limited pharmaco-
kinetic PK data are available alone in this setting. Major
side effects noted in these studies included thrombo-
cytopenia, hypercholesterolemia, hypertriglyceridemia, and
diarrhea. Renal function was not impaired.
The water-soluble rapamycin ester CCI-779 was selected
for clinical development through collaborative efforts
between Wyeth-Ayerst Laboratories and the National
Cancer Institute. In the US National Cancer Institute’s 60
tumor type-specific cell line screening panel, CCI-779 and
rapamycin had nearly identical growth inhibitory profiles
and 50% inhibitory concentration (IC50) values that were
frequently in the nanomolar range according to the
investigator brochure for CCI-779 formulation. Cell lines
derived from breast, prostate, and small cell lung cancer
were among the most sensitive to CCI-779. In further
laboratory-based studies by Wyeth, breast cancer cell lines
(BT-474, SK BR-3, and MCF-7) exhibited extraordinary
sensitivity to CCI-779, with IC50 values ranging from
0.0006 to 0.001 µmol/l [34]. Most breast cancer cell lines
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highly sensitive to CCI-779 were found to be estrogen
dependent, over-expressed Erb-2, and/or had PTEN
deletions [21]. The resistant breast cancer cell lines lacked
these features. Furthermore, sensitive breast cancer cell
lines generally had higher levels of activated Akt, perhaps
leading to downstream activation of mTOR and
subsequent sensitivity to mTOR inhibitors. Laboratory data
have also supported the synergistic growth inhibitory
effects of MCF-7 breast cancer cell lines and xenografts
with combinations of CCI-779 and ER antagonists.
Recently, both control MCF-7 and MCF-7/Aro (aromatase
expressing) cells were found to be sensitive to treatment
with the rapamycin analog RAD001 in vitro. RAD001 was
found to almost completely inhibit estradiol induced
proliferation in both control MCF-7 cells as well as estradiol
and androstenedione induced proliferation in MCF-7/Aro
cells, suggesting that mTOR signaling is required for
estrogen proliferative response in MCF-7 cells. Further-
more, combination therapy with letrozole and RAD001
resulted in increased inhibition of cell proliferation as well
as a synergistic effect, even at suboptimal levels of
RAD001. No evidence of antagonism was observed [36].
Human pharmacokinetics
The pharmacokinetic properties of rapamycin have been
studied in healthy individuals, pediatric dialysis patients,
hepatically impaired adult patients, and adult renal
transplant patients. Oral doses of both liquid and pill forms
of rapamycin are rapidly but variably absorbed. Mean time
to peak concentrations range from 1 hour in healthy
individuals to 2 hours in renal transplant patients. Half-life
is upwards of 2.5 days. Metabolism is by the intestinal and
hepatic CYP3A4 enzyme family, and 91% of the
elimination of the drug is via the gastrointestinal tract. The
area under the curve correlates well with peak and trough
concentrations.
Patients who ingested the drug after a high fat breakfast
did have a delayed time to maximum concentration
(Cmax), and it is recommended that rapamycin be
consistently taken with or without food. In a phase I
pharmacokinetic study conducted in renal transplant
patients, doses ranging from 0.5 to 6.5 mg/m2 were
administered every 12 hours. Phase III studies to date
have had concomitant use of cyclosporine or steroid, or
both. At a dose of 2 mg/day the rapamycin trough
concentration was 8.58 ± 4 ng/ml and at 5 mg/day the
trough was 17.3 ± 7.4 ng/ml. Rapamycin concentrations
in stable renal transplant patients are dose proportional
between 3 and 12 mg/m2. Also, in this population a
loading dose of three times the maintenance dose
provided a near steady state concentration within 1 day in
most patients. Stable renal transplant recipients have
received single doses of up to 21 mg/m2. No toxicity has
been observed in any of several single dosing studies with
rapamycin doses ranging from 3 to 21 mg/m2.
Development of mammalian target of
rapamycin inhibitors for cancer treatment
Based on preclinical studies suggesting that inhibition of
mTOR has antiproliferative effects in a variety of cancer
models, clinical studies were initiated with two rapamycin
analogs, namely RAD001 and CCI-779. Preliminary
results from these studies indicate that these drugs are
well tolerated and have promising anticancer activity [37].
The principal toxicities of CCI-779 – the agent for which
more clinical data are available – include thrombo-
cytopenia, hyperlipidemia, skin toxicity, and elevation in
liver function tests. These side effects were in general mild
to moderate in intensity and not necessarily associated
with administered dose of the drug. In addition, antitumor
activity was demonstrated in a variety of tumor types,
including breast cancer and renal cancer. A randomized
phase II study of multiple dose levels of CCI-779 in
patients with advanced refractory renal cell carcinoma has
shown antitumor activity and encouraging survival as well
as drug tolerability [38].
Additionally, a multicenter European phase II study was
conducted in 109 patients with advanced breast cancer
[39]. Patients who had progressed on taxanes and
anthracyclins were allowed to receive a weekly
intravenous dose of CCI-779 at either 75 mg or 225 mg.
Clinical benefit was observed in 37% of patients,
including 10 partial responses and 26 patients with stable
disease for longer than 8 weeks. Activity was seen at both
dose levels, with a low toxicity profile. It is interesting to
note that activity was even seen in patients with liver
metastases at both dose levels but no response was seen
in any of the 33 HER-2 negative patients. Further studies
were initiated because of these promising results.
Because of the association of hormone resistance and
activation of the PI3K and mTOR pathways, development
of clinical trials combining mTOR inhibitors and hormonal
agents are logical. A randomized phase III, placebo-
controlled, double-blind study of oral CCI-779
administered in combination with letrozole versus letrozole
alone in patients with estrogen-dependent breast cancer
is ongoing. Combinations of mTOR inhibitors and
cytotoxic agents are also expected.
Conclusion
The PI3K/Akt signaling pathway regulates many normal
cellular processes including cellular proliferation, survival,
growth and motility, all of which are critical processes for
tumorigenesis. It is clear that alteration of this pathway
occurs in many cancerous states, and perhaps targeted
manipulation to optimize control of this pathway will
mitigate its contribution to oncogenic activity. In several
cancers, mTOR inhibitors have been shown to be
promising agents in reducing tumor growth in vitro and in
vivo, including renal cancer and breast cancer. Hopefully,
with better understanding of these pathways and improved
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‘profiling’ of individual patients tumors, future clinical trials
and treatment options will identify and target those patients
who will benefit from these directed therapies.
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